Bioluminescence imaging of angiogenesis in a murine orthotopic pancreatic cancer model by Angst, Eliane et al.
B The Author(s), 2010
Published Online: 8 April 2010 DOI: 10.1007/s11307-010-0310-4
Mol Imaging Biol (2010) 12:570Y575
BRIEF ARTICLE
Bioluminescence Imaging of Angiogenesis
in a Murine Orthotopic Pancreatic Cancer Model
Eliane Angst,1,3,4 Monica Chen,1 Michelle Mojadidi,1 O. Joe Hines,1,2
Howard A. Reber,1,2 Guido Eibl1,2
1Hirshberg Laboratory for Pancreatic Cancer Research, Department of Surgery, UCLA Center for Excellence in Pancreatic Diseases,
David Geffen School of Medicine at UCLA, Los Angeles, CA( USA
2UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA( USA
3Department of Visceral and Transplant Surgery, Inselspital, University of Bern, Bern, Switzerland
4Department of Surgery, David Geffen School of Medicine at UCLA, 675 Charles E. Young Drive South, MRL 2535, Los Angeles, CA
90095, USA
Abstract
Purpose: Angiogenesis is essential for physiological processes as well as for carcinogenesis.
New approaches to cancer therapy include targeting angiogenesis. One target is VEGF-A and
its receptor VEGFR2. In this study, we sought to investigate pancreatic cancer angiogenesis in a
genetically modified VEGFR2-luc-KI mouse.
Procedures: Live in vivo bioluminescence imaging of angiogenesis was performed continuously
until sacrifice in subcutaneous tumors as well as in orthotopically transplanted tumors. Tumor
tissue was immunostained for CD-31 and VEGFR2.
Results: Peritumoral angiogenesis measured by light emission was detected beginning at
week 3 following subcutaneous injection. In the orthotopic model, light emission began at day 4,
which likely corresponds to wound healing, and continued throughout the experimental period
during tumor growth. Peritumoral CD-31 vessel- and VEGFR2-staining were positive.
Conclusions: The VEGFR2-luc-KI mouse is a valuable tool to demonstrate tumor angiogenesis
and seems to be suitable to evaluate anti-angiogenic approaches in pancreatic cancer.
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Introduction
Angiogenesis represents the formation of new capillariesby the outgrowth from existing microvessels. While
angiogenesis is essential for most physiological processes, e.g.,
embryonic development, menstrual cycle, and wound repair,
unregulated angiogenesis is involved in many pathological
conditions, including cancer. Tumor formation is a complex
process involving cell proliferation and cell death. In fact,
tumors cannot grow larger than a few millimeters without the
assembly of new blood vessels to supply the necessary
nutrients and oxygen. It is now clear that progression of tumor
growth and metastasis are angiogenesis dependent [1, 2]. This
phenomenon is called the angiogenic switch, which is depend-
ent on the balance between pro-angiogenic and anti-angiogenic
factors expressed by the tumor and the stromal cells. Failure of
a tumor to recruit new microvascular endothelial cells or to
reorganize the existing surrounding vasculature results in a
non-angiogenic tumor that is only microscopic in size (less
than 1 mm3), as the diffusion limit of oxygen is approximately
100 µm through tissue [2]. Small tumors are highly dependent
on their microenvironment for oxygen and the supply of
nutrients, whereas macroscopic tumors bear well-organized
vascular structures filled with red blood cells [2]. In contrast to
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normal vessels, tumor vascular structures are disorganized and
leaky.
Angiogenesis is a complex biological process that
involves a cascade of intra- and extracellular events.
Vascular endothelial growth factor (VEGF) is a very potent
and well-studied inducer of angiogenesis. Stimulated endo-
thelial cells produce proteases that degrade the surrounding
basement membrane. Endothelial cells and vascular smooth
muscle cells proliferate and migrate to align and form new
vessels. The endothelial cells produce specific growth
factors, such as platelet-derived growth factor and trans-
forming growth factor beta, to attract the supporting
pericytes. A new specific basement membrane is subse-
quently produced resulting in a mature vessel [3].
Proliferating endothelial cells in vessels undergoing active
angiogenesis express receptors for VEGF (VEGFR). Three
different VEGFRs have been identified and shown to be
sensitive to VEGF ligands. VEGFR1 and VEGFR2 are
expressed on vascular endothelial cells, but the biological
angiogenic activity is mainly mediated through VEGFR2 [3].
VEGFR3 is expressed on lymphatic endothelial cells and
receptor signaling induces lymphangiogenesis. Several
ligands bind and activate human VEGFR2, including
VEGF-A, processed VEGF-C and VEGF-D, VEGF isolated
from snake venom as well as VEGF-like proteins encoded by
parapox virus open reading frames (VEGF-E family). Murine
VEGF-D fails to bind to VEGFR2. Both human VEGF-D and
VEGF-C bind to VEGFR2 with an affinity one order of
magnitude weaker than VEGF-A. Therefore, the angiogenic
activity is mainly mediated through VEGFR2 and VEGF-A
[4]. Targeted inactivation of either VEGF-A or VEGFR2
interferes with angiogenesis. Indeed mouse embryos lacking
VEGF-A or VEGFR2 die at 8.5 or 9.5 embryonic days,
respectively [5]. In tumors, the levels of VEGFR2 mRNA are
significantly increased compared to normal tissues [6].
VEGF-A binding to VEGFR2 induces proliferation, migra-
tion, and differentiation of vascular endothelial cells [4].
VEGFR2 signaling encompasses a variety of coordinated
intracellular events. The activation of PI3K/Akt pathway leads
to cell survival while activation of the MEK/ERK pathways
appears to be crucially involved in mediating signals for
endothelial cell proliferation. Activation of FAK and paxillin
via tyrosine phosphorylation mediated by VEGFR2 also leads
to recruitment of actin-anchoring proteins—events thought to
be essential for vascular endothelial cell migration [7].
Newer approaches to cancer therapy involving the
blockade of angiogenesis represent a promising research
field [1, 8]. But methods to study angiogenesis in vivo with
longitudinal measurements over time are cumbersome and
limited, as it usually requires the sacrifice of the animal and
visualization of microvessels by immunohistochemical
staining of endothelial cell-specific markers. Novel and less
invasive approaches to study angiogenesis are needed in
preclinical studies to advance this field.
Therefore, we sought to use a murine angiogenesis model
which enables us to monitor VEGFR2 promoter activity. We
used the approach of genetically modified animals in which
the VEGFR2 promoter drives the expression of luciferase
and thus allows direct visualization of angiogenesis using
bioluminescence in vivo. We show here, for the first time,
the feasibility to image tumor angiogenesis with the
genetically modified VEGFR2-luc-KI mouse in an ortho-
topic pancreatic cancer model.
Materials and Methods
Reagents
Rat anti-mouse PECAM-1 (CD-31) antibody was purchased from
Angio-Proteomie (mAP-0032, Boston, MA, USA), and rabbit anti-
VEGFR2 antibody was from Cell Signaling Technology, Inc.
(Danvers, MA, USA). Heterozygous VEGFR2-luc-KI mice with a
nu/nu background were obtained from Xenogen, Caliper Life
Sciences, Inc. (Hopkinton, MA, USA). These mice were created
using a gene-targeting approach that “knocked in” firefly luciferase
cDNA into the first exon of the endogenous VEGFR2 locus in
murine 129/SvEv embryonic stem cells. Luciferin was provided by
the Crump Institute for Molecular Imaging at UCLA.
Orthotopic xenograft
Animal studies were approved by the Chancellor’s Animal
Research Committee of the University of California, Los Angeles,
in accordance with the National Institutes of Health Guide for the
Care and Use of Laboratory Animals. The orthotopic xenograft was
performed as described earlier [9]. Briefly, 2×106 HPAF-II
pancreatic cancer cells were injected subcutaneously into the flank
of two anesthetized donor nude mice. The donor tumors were
measured at the time of imaging in two dimensions. Tumor surface
was calculated from the length and the width with the formula
(length/2)×(width/2)×π. After 4 weeks, the donor tumor was
harvested and minced to fragments of approximately 1 mm3. Only
macroscopically viable tissue from the periphery of the subcuta-
neous tumor was used for the orthotopic transplantation. Three
recipient nude mice were anesthetized with isoflurane and opened
by a left longitudinal laparotomy. The spleen, together with the
pancreatic tail, was gently exteriorized, and a tissue pocket was
created in the pancreatic parenchyma. A tumor fragment was placed
into the tissue pocket so it was entirely surrounded by normal
pancreas. After careful relocation of the pancreas and spleen into
the abdominal cavity, the abdominal wall was closed in two layers.
Mice were imaged in regular intervals (see below). After 6 weeks,
the animals were imaged before and after sacrifice and evaluated
for tumor, ascites, and metastasis. Samples were preserved as
freshly frozen and in 10% formalin before processing.
Imaging
Imaging and recording was performed at days 15, 22, 25, and 28
after the subcutaneous injection and at days 4, 8, 14, 23, 30, 37, and
45 after tumor implantation into the orthotopic position at the
Imaging Core Facility at UCLA. After anesthesia with isoflurane,
the mice were injected intraperitoneally with 3 mg luciferin. In the
first week, we showed in a time-course experiment over 30 min that
the light emission was stable 10 min after the injection. At each day
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of imaging, several measurements were taken between 10 and
25 min after injection. Imaging and data processing were performed
in an IVIS™ 100 Imaging System with the Living Image® 2.50.1
software: a photographic image was taken and then the light
acquisition was performed for bioluminescence. Both pictures were
superimposed. Light intensity was quantified in the region of
interest. Output was expressed in photons/s/cm2/steridian. Three to
four measurements were averaged for each animal. Data are
presented as mean±standard deviation (SD) of the measurement
at each time point.
Immunohistochemistry
Four-micrometer cryostat sections were fixed in acetone. Endoge-
nous peroxidase activity was blocked in 3% hydrogen peroxide and
background was blocked with 20% normal serum (from the same
animal species as the secondary antibody) for 1 h at room
temperature. The sections were incubated with the anti-CD-31
antibody for 2 h at room temperature, including negative controls
that were performed by omission of the primary antibody. The
biotinylated secondary antibody was followed by components of
the Vectastain® Kit (Vector Laboratories Inc., Burlingame, CA,
USA) according to the manufacturer’s instruction. Immunoreactiv-
ity was developed using 3,3′-diaminobenzidine as the peroxidase
substrate and nuclei were counterstained with hematoxylin. A
similar technique was applied for VEGFR2 staining on paraffin
sections except for antigen retrieval in citrate buffer, incubation of
the sections with the anti-VEGFR2 antibody overnight at 4°C, and
an isotype IgG for negative control. Serial sections were stained
with hematoxylin and eosin and documented using a Nikon Eclipse
90i microscope and NIS-Elements AR 3.0 software from Nikon
Instruments Inc. (Melville, NY, USA).
Results
To assess whether we could visualize tumor angiogenesis
after subcutaneous injection of pancreatic cancer cells, the
donor mice were imaged after the initial appearance of a
macroscopically visible tumor after day 14. Although the
tumor started to be visible and palpable, light emission in the
peritumoral region stayed at background values (Fig. 1).
These animals have a relatively high background of
VEGFR2-promoter activity, corresponding to light emission
of about 3.5×106 photons/s/cm2/steridian. We found even
higher unstimulated light emission in the testicles, presum-
ably intra-abdominal reproductive organs, liver, and spleen.
Consistent with these results VEGFR-2 has been found to be
expressed in the Leydig cells of the testicles and in normal
hepatic tissue [10, 11]. Spleen and liver bear an intricate
network of vessels requiring constant remodeling of the
capillaries which may account for the observed VEGFR2
promoter activity. Over the next 2 weeks, there was a 2.7-
fold increase in light emission at the tumor site (9×106
photons/s/cm2/steridian). The measured elevation in light
emission paralleled the increase of the tumor surface area
(Fig. 1, inset).
After tumor implantation in the orthotopic position, the
animals were imaged at day 4 and a specific light emission
at the site of implantation about 3-fold over background
values was already observed (1.1×107 photons/s/cm2/steri-
dian; Fig. 2). The light emission peaked at day 8 (1.5×107
photons/s/cm2/steridian) and then returned to initial values at
day 14. This first peak most likely corresponded to wound
healing. Accordingly, after surgery the abdominal wound
had initially a fibrinous coating and was completely healed
at day 14. After day 14, the light emission increased again
gradually at the site of implantation with a second peak at
day 30 (2.1×107 photons/s/cm2/steridian). Thereafter, the
light signal decreased with a final value of 1.4×107 photons/
s/cm2/steridian at day 45. Overall, the specific light emission
at the implantation site was about 2-fold higher at day 30
compared to day 4, suggesting locally elevated VEGFR2
promoter activity and angiogenesis at the tumor site. In all
the measurements, the small variation between sampled
images indicates stable light emission over time.
After 6 weeks, each animal was individually imaged pre-
and post-mortem. Luciferin was injected and light emission
in the anesthetized living animal was measured. Then a final
laparotomy was performed and the orthotopically grown
tumors were removed. In one mouse, a tumor ventral to the
spleen and a second tumor growing orthotopically in the tail
of the pancreas was found (Fig. 3). Both tumors and the skin
covering the tumors were removed. The animals were
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Fig. 1. Imaging of a subcutaneous donor tumor. Male donor
VEGFR2-luc-KI mice were injected with 2×106 cells sub-
cutaneously. They were imaged as described in “Materials
and Methods” section. These mice have a relatively high
background of VEGFR2 promoter activity and specific
activity in the testicles, the intra-abdominal sexual organs,
spleen, and liver. There was a steady increase in light
emission at the tumor site over time. The insert shows the
increase in tumor area (mm2). Error bars represent the SD of
the measurement at each time point.
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euthanized and all removed parts were separately imaged
again. After tumor harvest, only the background level of
3.5×106 photons/s/cm2/steridian, corresponding to 26% of
the initial light emission, remained in the euthanized animal,
indicating the removal of all the tissue with induced
luciferase activity. Separate measurements demonstrated
strong luciferase activity in the first ventral tumor (86% of
the initial measurement) and the second orthotopic tumor
(56%). The skin covering the intra-abdominal tumors only
accounted for 4% of the initial light emission. Addition of
light emission from the different parts after sacrifice is larger
than the total light emission before sacrifice due to the
absorbance caused by the overlaying tissue in the live
animal. We found locally growing tumors without any
apparent ascites and no distant metastasis in all the animals.
To assess whether the measured light emission corre-
sponded to the presence of blood vessels, frozen tissue was
processed and stained for the endothelial cell marker CD-31
(Fig. 4). Immunohistochemical staining for CD-31 not only
showed mainly peritumoral vessels but also intratumoral
vessels within the stromal tissue between cancer cells. In
addition, VEGFR2, another marker of endothelial cells, was
found to be faintly expressed on peritumoral vessels (Fig. 4).
Discussion
The current study demonstrates the feasibility to monitor
angiogenesis in longitudinal measurements in a VEGFR2-
luc-KI mouse applying an orthotopic pancreatic cancer
model. Due to the low background activity of the VEGFR2
promoter in the pancreas, this mouse is suited to study local
tumor growth with its accompanying angiogenesis and
wound healing. In contrast, a metastatic model would be
difficult to investigate for the high background activity
found in several other organs.
In vivo analysis of tumor angiogenesis is a crucial step to
evaluate therapeutic anti-angiogenic strategies and the
involved regulatory pathways. Histological and molecular
techniques allow analyses on the subcellular and molecular
level. However, they are not suitable for longitudinal
functional studies. Intravital microscopy has a high spatial
resolution, but the necessary tissue preparation affects the
physiology of angiogenesis and the depth of imaging is only
several hundred microns within living tissue [12]. This is not
feasible for the pancreas, which lies in the depth of the
abdomen. Non- or minimally invasive imaging techniques
can obtain temporal dynamics and quantitatively determine
physiological functions. VEGFR2 imaging has been per-
formed previously with success, particularly in angiogene-
sis-directed treatment studies [13–16]. Contrast-enhanced
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Fig. 2. Imaging of an orthotopic tumor. Pieces of the donor tumors were transplanted into male recipient VEGFR2-luc-KI mice,
which were imaged weekly. Localized light emission was detected. Error bars represent the SD of the measurement at each
time point.
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Fig. 3. Imaging at sacrifice. After 6 weeks of tumor growth,
the animals were imaged in vivo and post-mortem. The
animal, tumors, and the skin which covered the tumors were
imaged and quantified separately. In the post-mortem imag-
ing, the total light emission is stronger because no light is
absorbed through the tissue. Error bars represent the SD of
the measurement at each time point.
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ultrasound using microbubbles targeted to VEGFR2 has
been used in several preclinical studies [15–17]. Positron
emission tomography or single photon emission computed
tomography using radiotracers labeling VEGF or monoclo-
nal antibodies specific to VEGFR2 has been shown to detect
molecular targets defining vessels, but have the inconven-
ience of using radioactivity [13, 18, 19]. Fluorescent proteins
and bioluminescence both are non-invasive, non-radioactive,
and technically easy to handle [20]. Monoclonal antibodies
labeled with fluorescence demonstrated differences in
VEGFR2 expression [14]. In contrast to fluorescence,
bioluminescence is more sensitive for imaging and lacks
the background from autofluorescence [21]. Transgenic and
knock-in animals expressing luciferase under the VEGFR2
promoter have been successfully used to visualize wound
healing and peritumoral angiogenesis [22–24]. In these
animal models, promoter activation/gene expression is
measured by bioluminescence, rather than protein expres-
sion. In the present study, we used “knock-in” animals,
which assure physiological levels of VEGFR2 promoter
activation and protein expression.
The subcutaneous donor tumor induced VEGFR2 pro-
moter activity only after growth to a certain size. In contrast,
the implantation of the orthotopic tumor piece induced
stronger VEGFR2 promoter activity. Performing a laparot-
omy creates a large area of wound healing, whereas a
subcutaneous injection only induces small tissue damage.
After the first period of wound healing, the light emission
increased gradually to a second peak at 30 days and
decreased thereafter. After growth to a certain size, tumors
develop central necrosis, decreasing the mass of viable cells
and thus the secretion of pro-angiogenic factors like VEGF-
A. This may be the reason for decreased VEGFR2 promoter
activity and light emission after 30 days. But the level of
light emission was still increased 4-fold compared to the
background levels. Considering that bioluminescent light
emission is being absorbed by the tissue, the same level of
promoter activity results in a stronger light emission if the
source is more superficial in the mouse. Tumor removal at
sacrifice resulted in light emission at background levels for
the mouse. This argues for the removal of the specific
tumor-associated VEGFR2 promoter activity by explanting
the tumors and the skin. The covering skin emitted only low
levels of light, confirming the completion of wound healing.
The highest light emission was found peritumorally. To
confirm angiogenesis, we stained the tumor tissue for CD-31
and VEGFR2. VEGFR2 expression was not present in all
the CD-31-positive vessels and was mainly expressed in
peritumoral vessels. This is consistent with VEGFR2 acting
in concert with VEGF-A as promoters of neoangiogenesis,
but not as sustainer of vessel structures once the vessels are
formed. As the present study was conducted to evaluate the
feasibility to image angiogenesis in the VEGFR2-luc-KI
mouse, the interpretation of the histological data is limited.
A larger, subsequent study will be required to assess the
quantitative correlation between bioluminescent light emis-
sion and VEGFR2 expression.
Pancreatic cancer is characterized by a strong desmo-
plastic reaction that drives the expression of factors
responsive to hypoxia including VEGF-A, inducing the
formation of new vessels. Preclinical studies have found that
targeting cancer-derived angiogenesis, specifically VEGF,
can slow the progression of pancreatic cancer in vivo [25–
28]. However, the application of this work in clinical trials
has been disappointing to date [29]. While VEGF is a prime
angiogenic factor, it is increasingly apparent that other
angiogenic factors binding to different receptors contribute
to the overall angiogenic cancer milieu. Therefore, a
preclinical model visualizing angiogenesis is valuable to
test new targets. VEGFR2-luc-KI mice are available under a
C57/BL6 background. This enables the exploration of
regulatory mechanisms in tumor angiogenesis by using
various genetically modified mice. Future studies are
warranted to demonstrate whether this promising approach
Fig. 4. Immunohistochemistry for CD-31 and VEGFR2. The peritumoral area shows distinct staining for CD-31 and weak
staining for VEGFR2.
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is suitable to detect the angiogenic switch in transgenic mice
of pancreatic carcinogenesis.
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